Overview

A Study to Assess the Safety and Tolerability of LB-P6 and LB-P8 in Healthy Participants

Status:
Not yet recruiting
Trial end date:
2022-01-14
Target enrollment:
Participant gender:
Summary
The study is designed to assess the safety and tolerability of multiple ascending doses of LB-P6 or LB-P8 in healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
LISCure Biosciences
LISCure Biosciences AUS Pty LTD
Collaborator:
Novotech (Australia) Pty Limited